1 |
Mu, J., J. Woods, Y. P. Zhou, R. S. Roy, Z. Li, E. Zycband, Y. Feng, L. Zhu, L. C., A. D. Howard, D. E. Moller, N. A. Thonberry, and B. B. Zhang. 2006. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55: 1695-1704.
DOI
|
2 |
Xu, G., D. A. Stoffers, J. F. Habener, and S. Bonner-Weir. 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276.
DOI
|
3 |
Butler, A. E., M. Campbell-Thompson, T. Gurlo, D. W. Dawson, M. Atkinson, and P. C. Butler. 2013. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62: 2595-2604.
DOI
|
4 |
Cho, J. M., H. W. Jang, H. Cheon, Y. T. Jeong, D.-H. Kim, Y.-M. Lim, S.-h. Choi, E.-K. Yang, C.-Y. Shin, M.-H. Son, S. H. Kim, H.-J. Kim, and M.-S. Lee. 2011. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing -cell replication and neogenesis. Diabetes Res. Clin. Pract. 91: 72-79.
DOI
|
5 |
Kim, D. H., J.-C. Lee, M.-K. Lee, K.-W. Kim, and M.-S. Lee. 2012. Treatment of autoimmune diabetes by toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition. Diabetologia 55: 3308-3317.
DOI
|
6 |
Jeon, K., H. Lim, J. H. Kim, N. V. Thuan, S. H. Park, Y. M. Lim, H. Y. Choi, E. R. Lee, J. H. Kim, M. S. Lee, and S.-G. Cho. 2012. Differentiation and Transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. Stem Cells Dev. 21: 2642-2655.
DOI
|
7 |
Turley, S., L. Poirot, M. Hattori, C. Benoist, and D. Mathis. 2003. Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J. Exp. Med. 198: 1527-1537.
DOI
|
8 |
Finegood, D. T., M. D. MaArthur, D. Kojwang, M. J. Thomas, B. G. Topp, T. Leonard, and R. E. Buckingham. 2001. -cell mass dynamics in Zucker Diabetic Fatty rats. Diabetes 50: 1021-1029.
DOI
|
9 |
Kim, Y.-H., S. Kim, K.-A. Kim, H. Yagita, N. Kayagaki, K.-W. Kim, and M.-S. Lee. 1999. Apoptosis of pancreatic -cells detected in accelerated diabetes of NOD mice:no role of Fas-Fas ligand interaction in autoimmune diabetes. Eur. J. Immunol. 29: 455-465.
DOI
|
10 |
O'Brien, B. A., B. V. Harmon, D. P. Cameron, and D. J. Allan. 1997. Apoptosis is the mode of -cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse. Diabetes 46: 750-757.
DOI
|
11 |
Trudeau, J. D., J. P. Dutz, E. Arany, D. J. Hill, W. E. Fieldus, and D. T. Finegood. 2000. Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? Diabetes 49: 1-7.
DOI
|
12 |
Kim, H. S., M. S. Han, K. W. Chung, S. Kim, E. Kim, M. J. Kim, E. Jang, H. A. Lee, J. Youn, S. Akira, and M.-S. Lee. 2007. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27: 321-333.
DOI
|
13 |
Diana, J., Y. Simoni, L. Furio, L. Beaudoin, B. Agerberth, F. Barrat, and A. Lehuen. 2013. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 19: 65-73.
DOI
|
14 |
Cavaillon, J. M., C. Adrie, C. Fitting, and M. Adib-Conquy. 2003. Endotoxin tolerance: is there a clinical relevance? J. Endotoxin Res. 9: 101-107.
DOI
|
15 |
Kim, D. H., J.-C. Lee, S. Kim, S. H. Oh, M.-K. Lee, K.-W. Kim, and M.-S. Lee. 2011. Inhibition of autoimmune diabetes by TLR2 tolerance. J. Immunol. 187: 5211-5220.
DOI
|
16 |
Xiong, Y., M. Pennini, S. N. Vogel, and A. E. Medvedev. 2013. IRAK4 kinase activity is not required for induction of endotoxin tolerance but contributes to TLR2-mediated tolerance. J. Leukocyte Biol. 94: 291-300.
DOI
|